Diageo, UP Fintech, Regencell Bioscience, RBB Bancorp, and China SXT Pharmaceuticals are the five Chinese stocks to watch today, according to MarketBeat's stock screener tool. “Chinese stocks” generally refers to shares in companies based in or closely tied to China, including those listed on mainland Chinese exchanges, Hong Kong, or overseas markets such as the United States. For investors, the term can cover different share classes and listing structures, which may carry distinct rules, risks, and access requirements. These companies had the highest dollar trading volume of any Chinese stocks within the last several days.
Diageo (DEO)
Diageo plc, together with its subsidiaries, engages in the production, marketing, and sale of alcoholic beverages. The company offers scotch, gin, vodka, rum, raki, liqueur, wine, tequila, Chinese white spirits, cachaça, and brandy, as well as beer, including cider and flavored malt beverages. It also provides Chinese, Canadian, Irish, American, and Indian-Made Foreign Liquor whiskies, as well as flavored malt beverages, ready to drink, and non-alcoholic products.
NYSE DEO traded up $0.43 during trading hours on Friday, reaching $100.69. 644,363 shares of the company were exchanged, compared to its average volume of 1,443,984. Diageo has a 1 year low of $72.45 and a 1 year high of $102.74. The company has a debt-to-equity ratio of 1.53, a quick ratio of 0.62 and a current ratio of 1.60. The business's 50 day simple moving average is $89.85 and its 200-day simple moving average is $86.04.
Read Our Latest Research Report on DEO
UP Fintech (TIGR)
UP Fintech Holding Limited provides online brokerage services focusing on Chinese investors. The company has developed a brokerage platform, which allows investor to trade stocks, options, warrants, and other financial instruments that can be accessed through its APP and website. It offers brokerage and value-added services, including investor education, community engagement, and IR platform services.
Shares of TIGR stock traded up $0.15 during trading hours on Friday, reaching $3.90. The stock had a trading volume of 1,025,546 shares, compared to its average volume of 3,090,932. The stock's fifty day simple moving average is $4.48 and its 200 day simple moving average is $5.76. The firm has a market capitalization of $740.77 million, a PE ratio of 6.62 and a beta of 0.65. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.06. UP Fintech has a 12 month low of $3.61 and a 12 month high of $11.35.
Read Our Latest Research Report on TIGR
Regencell Bioscience (RGC)
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.
RGC stock traded down $0.12 during mid-day trading on Friday, hitting $5.15. 75,793 shares of the stock were exchanged, compared to its average volume of 294,242. Regencell Bioscience has a 12 month low of $4.51 and a 12 month high of $69.00. The business has a fifty day moving average price of $6.86 and a 200 day moving average price of $16.69.
Read Our Latest Research Report on RGC
RBB Bancorp (RBB)
RBB Bancorp operates as the bank holding company for Royal Business Bank that provides various banking products and services to the Chinese-American, Korean-American, and other Asian-American communities. Its deposit products include checking, savings, and money market accounts, as well as certificates of deposit.
RBB stock traded down $0.09 during midday trading on Friday, hitting $25.61. The company had a trading volume of 8,460 shares, compared to its average volume of 113,589. The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.55. The stock has a market cap of $433.41 million, a price-to-earnings ratio of 9.93 and a beta of 1.06. RBB Bancorp has a 52 week low of $18.45 and a 52 week high of $28.24. The stock's 50 day moving average price is $26.21 and its 200 day moving average price is $24.49.
Read Our Latest Research Report on RBB
China SXT Pharmaceuticals (SXTC)
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.
NASDAQ SXTC traded up $0.01 during trading on Friday, hitting $2.94. The company had a trading volume of 24,197 shares, compared to its average volume of 69,616. The company has a quick ratio of 7.76, a current ratio of 7.94 and a debt-to-equity ratio of 0.02. China SXT Pharmaceuticals has a one year low of $2.71 and a one year high of $8,375,880.00. The company's fifty day moving average is $145.78 and its 200-day moving average is $14,158.19.
Read Our Latest Research Report on SXTC
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Diageo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diageo wasn't on the list.
While Diageo currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
